Treating Laryngeal Hyperfunction With Flow Phonation
1 other identifier
interventional
60
1 country
1
Brief Summary
The purposes of the proposed study are: a) to determine whether Flow Phonation can decrease Laryngeal Resistance (Rlaw) in patients with Muscle Tension Dysphonia (MTD); and b)establish the relationship between changes in measures of Rlaw and phonatory airflow to endoscopic, perceptual, acoustic, and handicap assessment ratings. MTD can have a debilitating effect on individuals who rely on their voices the most-teachers, preachers,salespeople, singers-costing them time, money, and even their jobs. It can lead to vocal fatigue, pain, and complete loss of voice. While treatments have emerged with some promising effects, no treatments have proven to have long-term benefits to all patients. Our preliminary data demonstrate Flow Phonation training resulted in significant decreases in Laryngeal Resistance to phonatory airflow with associated improvements in voice quality and voice handicap ratings. Sample size for our pilot study was small; no control group was utilized; and outcome measures were limited. In the proposed investigation, a larger sample will be obtained, a control group of participants receiving only Vocal Hygiene Training will be used for comparison during the first 3 weeks, and a wider range of outcome measures will be included over a longer period of time (1 year).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Dec 2013
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 16, 2013
CompletedFirst Posted
Study publicly available on registry
November 20, 2013
CompletedStudy Start
First participant enrolled
December 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2016
CompletedNovember 20, 2013
November 1, 2013
2.9 years
September 16, 2013
November 13, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Laryngeal Airway Resistance (Rlaw) Change Over Time
Measured using the KayPENTAX Phonatory Aerodynamic System during a voice efficiency task (i.e., repeating "apapapapapapapa."
3 weeks, 6 weeks, 12 weeks, 6 months, 12 months
Secondary Outcomes (3)
Voice Handicap Index (VHI)
3 weeks, 6 weeks, 12 weeks, 6 months, 12 months
Consensus Auditory Perceptual Evaluation - Voice
3 weeks, 6 weeks, 12 weeks, 6 months, 12 months
Noise-to-Harmonic Ratio
3 weeks, 6 weeks, 12 weeks, 3 months, 12 months
Study Arms (2)
12 Exercise Sessions
EXPERIMENTALPatients will receive 12 treatment sessions with flow phonation exercises, as well as education on vocal hygiene.
6 Hygiene and 6 Exercise
ACTIVE COMPARATORPatients will receive 6 sessions of vocal hygiene training for initial comparison to patients in Arm 1. They will then receive 6 sessions of vocal exercise training and vocal hygiene training combined.
Interventions
Patients will receive education on how to care for their voices on three factors: 1) hydration, 2) exogenous inflammation control, and 3) abstinence of yelling and screaming.
Three exercises are employed: gargling, cup bubble blowing, and stretch and flow (tissue blowing). Each is done without voicing, with voicing, and then with variations in pitch and verbalization.
Eligibility Criteria
You may qualify if:
- Rlaw greater than 1 standard deviation above or below mean
- Voice Handicap Index of greater than 18
- CAPE-V severity of 20 or greater
- willing to sign informed consent
- women must not have experienced menopause or be pregnant
You may not qualify if:
- organic lesion of the vocal folds
- history of neurologic disease
- history of head and neck cancer
- pulmonary disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Central Arkansas
Conway, Arkansas, 72035, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Gary H McCullough, Ph.D.
University of Central Arkansas
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor, Interim Dean of Graduate School
Study Record Dates
First Submitted
September 16, 2013
First Posted
November 20, 2013
Study Start
December 1, 2013
Primary Completion
November 1, 2016
Study Completion
November 1, 2016
Last Updated
November 20, 2013
Record last verified: 2013-11